Baxter International Inc (BAX) : Beese Fulmer Investment Management scooped up 73 additional shares in Baxter International Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 44,057 shares of Baxter International Inc which is valued at $2,120,023.Baxter International Inc makes up approximately 0.59% of Beese Fulmer Investment Management’s portfolio.
Other Hedge Funds, Including , Zurcher Kantonalbank (zurich Cantonalbank) reduced its stake in BAX by selling 73,898 shares or 48.58% in the most recent quarter. The Hedge Fund company now holds 78,224 shares of BAX which is valued at $3,764,139. Baxter International Inc makes up approx 0.05% of Zurcher Kantonalbank (zurich Cantonalbank)’s portfolio. Spectrum Management Group sold out all of its stake in BAX during the most recent quarter. The investment firm sold 175 shares of BAX which is valued $8,404.Umb Bank N Amo reduced its stake in BAX by selling 2,592 shares or 8.19% in the most recent quarter. The Hedge Fund company now holds 29,042 shares of BAX which is valued at $1,403,309. Baxter International Inc makes up approx 0.06% of Umb Bank N Amo’s portfolio. Pioneer Trust Bank N Aor added BAX to its portfolio by purchasing 4,480 company shares during the most recent quarter which is valued at $208,544. Baxter International Inc makes up approx 0.12% of Pioneer Trust Bank N Aor’s portfolio. Central Bank Trust Co sold out all of its stake in BAX during the most recent quarter. The investment firm sold 100 shares of BAX which is valued $4,682.
Baxter International Inc closed down -0.04 points or -0.08% at $48.08 with 46,07,929 shares getting traded on Thursday. Post opening the session at $48.09, the shares hit an intraday low of $47.75 and an intraday high of $48.35 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Baxter International Inc reported $0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.40. The company had revenue of $2585.00 million for the quarter, compared to analysts expectations of $2516.16 million. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 EPS.
Investors should note that on Jul 19, 2016, Baxter International Inc announced a cash dividend of $0.1300. The company’s management has announced Aug 31, 2016 as the ex-dividend date and fixed the record date on Sep 2, 2016. The payable date has been fixed on Oct 3, 2016.
Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Jul 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 50 from a previous price target of $47 .Baxter International Inc was Resumed by JP Morgan to “Neutral” on Jun 6, 2016.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.